Clinical research
Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology
Acacia Pharma Group plc welcomes an editorial published in the leading peer-reviewed journal Anesthesia & Analgesia, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS® as treatment of post-operative nausea & vomiting in patients who had not received prior prophylaxis*.
In late June, Minovia Therapeutics dosed the first patient in a Phase I/II clinical trial with Pearson syndrome. The company is one of the first to make headway in treating rare mitochondrial diseases.
In all three cancer types, data showed prolonged and consistent improvements in progression-free survival (PFS) that is similar to that seen with checkpoint inhibitor monotherapy.
According to reports, Novartis veteran Jonathan Symonds is likely to be named the next chairman of the board.
The beginning of virtual clinical trials is going to be a game-changer. Why they are going to be game-changer? What changes will occur? Know it all here.
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndrome
Prescient Therapeutics Limited, a clinical stage oncology company, announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.
PRESS RELEASES